CardiovascularResearch Phase

Atrial Natriuretic Peptide (ANP)

Endogenous

Overview

Atrial natriuretic peptide is a 28-amino acid endogenous hormone secreted primarily by atrial cardiomyocytes in response to atrial stretch and volume expansion. It binds to natriuretic peptide receptor A, activating guanylyl cyclase to produce cyclic GMP, which mediates vasodilation, natriuresis, and inhibition of aldosterone and renin secretion.

Mechanism of Action

ANP plays a critical role in cardiovascular homeostasis and blood pressure regulation..

Research Summary & Key Findings

ANP is an endogenous regulatory peptide rather than a therapeutic agent itself, though its recombinant form carperitide is approved in Japan. Plasma ANP levels serve as a biomarker in heart failure assessment, with elevations correlating with disease severity and prognosis in numerous observational studies.

Clinical Status

Research Phase

Atrial Natriuretic Peptide (ANP) is in the research phase with limited clinical data in humans. Current evidence is primarily derived from preclinical (animal or in vitro) studies.

Administration Routes

Endogenous

Related Peptides in Cardiovascular

Find a Provider

Find a verified provider who offers Atrial Natriuretic Peptide (ANP) therapy in your area.

Browse Provider Map

Find a Pharmacy

Browse PCAB-accredited and FDA 503B-registered compounding pharmacies that supply Atrial Natriuretic Peptide (ANP).

Pharmacy Directory

Join the Association

Access exclusive peptide protocols, provider resources, and community support.

List Your Practice

Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol.